{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T13:45:02Z","timestamp":1792071902078,"version":"4.4.0"},"reference-count":40,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T00:00:00Z","timestamp":1668988800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["acsjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2023,1,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Antibody\u2013drug conjugates (ADCs) have complex molecular structures and have been tested in numerous clinical trials. Therefore, understanding the mechanisms of their toxicity when applied in medical practice is of high importance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In a systematic review and meta\u2010analysis of data gathered from different scientific databases (PubMed, Embase, Cochrane, and Web of Science) between January 1, 2000, and June 7, 2022, the authors applied a random\u2010effects model with logit transformation and evaluated the heterogeneity between studies using I\n                      <jats:sup>2<\/jats:sup>\n                      statistics. The primary outcome was the incidence and 95% confidence interval (CI) for all\u2010grade and grade \u22653 treatment\u2010related adverse events and differences between different drugs, molecular structures, and cancer types.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In total, 2511 records were identified that included 169 clinical trials involving 22,492 patients. The overall incidence of treatment\u2010related adverse events was 91.2% (95% CI, 90.7%\u201391.7%; I\n                      <jats:sup>2<\/jats:sup>\n                      \u00a0=\u00a095.9%) for all\u2010grade adverse events and 46.1% (95% CI, 45.2%\u201347.0%; I\n                      <jats:sup>2<\/jats:sup>\n                      \u00a0=\u00a096.3%) for grade \u22653 adverse events. The most common all\u2010grade adverse events were lymphopenia (53.0%; 95% CI, 48.7%\u201357.3%), nausea (44.1%; 95% CI, 43.2%\u201344.9%), neutropenia (43.7%; 95% CI, 42.6%\u201344.9%), blurred vision (40.5%; 95% CI, 37.4%\u201343.6%), and peripheral neuropathy (39.6%; 95% CI, 38.2%\u201341.1%); and the most common grade \u22653 adverse events were neutropenia (31.2%; 95% CI, 30.2%\u201332.3%), hypoesthesia (23.3%; 95% CI, 10.6%\u201335.9%), thrombocytopenia (22.6%; 95% CI, 21.3%\u201323.9%), febrile neutropenia (21.2%; 95% CI, 19.3%\u201323.1%), and lymphopenia (21.0%; 95% CI, 18.2%\u201323.7%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Different ADCs appear to affect various treatment\u2010related adverse events and provide comprehensive data on treatment\u2010related adverse events for ADCs. The current results provide an important reference for clinicians and patients on how to care for toxicities from ADCs in clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Lay summary<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>\n                            Unique anticancer drugs called\n                            <jats:italic>antibody<\/jats:italic>\n                            <jats:italic>\u2013drug conjugates<\/jats:italic>\n                            (ADCs) have made significant progress in oncology in recent years because of their great success, and they are rapidly being used in the clinic as well as in hundreds of ongoing trials exploring their further use.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            The occurrence of serious side effects (\n                            <jats:italic>adverse events<\/jats:italic>\n                            ) related to the receipt of ADCs was studied using data from 169 clinical trials involving 22,492 patients to determine the treatment\u2010related causes of higher toxicity and adverse events in patients who receive ADCs, because these data are crucial for informing physicians how to safely treat patients using ADCs.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>The results indicate that different ADCs appear to affect various adverse events related to their use, providing comprehensive data on these ADCs that provide an important reference for clinicians and patients on how to care for toxicities from ADCs in clinical practice.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cncr.34507","type":"journal-article","created":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T04:40:55Z","timestamp":1669005655000},"page":"283-295","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":186,"title":["Treatment\u2010related adverse events of antibody\u2013drug conjugates in clinical trials: A systematic review and meta\u2010analysis"],"prefix":"10.1002","volume":"129","author":[{"given":"Youwen","family":"Zhu","sequence":"first","affiliation":[{"name":"Department of Oncology Xiangya Hospital Central South University  Changsha Hunan China"},{"name":"National Clinical Research Center for Geriatric Disorders Xiangya Hospital Central South University  Changsha Hunan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Oncology Xiangya Hospital Central South University  Changsha Hunan China"},{"name":"National Clinical Research Center for Geriatric Disorders Xiangya Hospital Central South University  Changsha Hunan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kailing","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology Xiangya Hospital Central South University  Changsha Hunan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3659-8070","authenticated-orcid":false,"given":"Hong","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Oncology Xiangya Hospital Central South University  Changsha Hunan China"},{"name":"National Clinical Research Center for Geriatric Disorders Xiangya Hospital Central South University  Changsha Hunan China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,11,21]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470\u20102045(16)30030\u20104"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140\u20106736(19)31774\u2010x"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25204764"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21705"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11523\u2010022\u201000872\u20103"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2018.1478725"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019\u20100098"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.ccr\u201014\u20100012"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571\u2010021\u201000470\u20108"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2016.268"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1177\/0192623318803059"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637\u2010017\u20100520\u20106"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.557"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7109.629"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.6.676"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.698"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0006\u2010341x.2000.00455.x"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.ED000142"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2016.1156829"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2014.10.021"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2009.25.1900"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2001.19.13.3244"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008\u20105472.can\u201006\u20104303"},{"key":"e_1_2_10_26_1","unstructured":"Genentech Inc.Kadcyla prescribing information. Genentech Inc;2015."},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1002965"},{"key":"e_1_2_10_28_1","volume-title":"Adcetris (brentuximab vedotin) prescribing information","author":"Seattle Genetics","year":"2015"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/now257"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637\u2010014\u20100151\u20100"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040620712443076"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1097\/cad.0b013e32801403f4"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2003.05.137"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262\u2010012\u20101369\u20103"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1209124"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1914510"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470\u20102045(19)30328\u20106"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmcibr1203156"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v93.11.3678.411k24_3678_3684"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2011.41.5851"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.ccr\u201006\u20100910"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.34507","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cncr.34507","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.34507","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:43:10Z","timestamp":1760276590000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.34507"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,21]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,1,15]]}},"alternative-id":["10.1002\/cncr.34507"],"URL":"https:\/\/doi.org\/10.1002\/cncr.34507","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,21]]},"assertion":[{"value":"2022-08-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}